Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · IEX Real-Time Price · USD
47.44
-0.05 (-0.11%)
May 3, 2024, 11:34 AM EDT - Market open
Apellis Pharmaceuticals Employees
Apellis Pharmaceuticals had 702 employees on December 31, 2023. The number of employees decreased by 65 or -8.47% compared to the previous year.
Employees
702
Change (1Y)
-65
Growth (1Y)
-8.47%
Revenue / Employee
$564,944
Profits / Employee
-$753,031
Market Cap
5.72B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 702 | -65 | -8.47% |
Dec 31, 2022 | 767 | 291 | 61.13% |
Dec 31, 2021 | 476 | 102 | 27.27% |
Dec 31, 2020 | 374 | 139 | 59.15% |
Dec 31, 2019 | 235 | 148 | 170.11% |
Feb 26, 2019 | 87 | 48 | 123.08% |
Feb 28, 2018 | 39 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Grifols | 23,737 |
Acadia Healthcare Company | 23,500 |
DENTSPLY SIRONA | 15,000 |
Option Care Health | 7,802 |
Exelixis | 1,310 |
Ionis Pharmaceuticals | 927 |
Glaukos | 907 |
APLS News
- 2 days ago - Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - GlobeNewsWire
- 2 days ago - Apellis Pharmaceuticals stock has lost 40% in 2024: buy the dip? - Invezz
- 7 days ago - Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - GlobeNewsWire
- 10 days ago - Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire